low - Home healthcare demand is non-discretionary and driven by chronic disease prevalence, aging demographics, and hospital discharge patterns rather than GDP growth. Medicaid/Medicare reimbursement provides revenue stability through economic cycles. However, state budget pressures during recessions can delay Medicaid rate increases, and unemployment spikes may temporarily improve nurse labor supply.

Rising interest rates increase borrowing costs on the company's $800M+ debt load (primarily variable-rate term loans), directly pressuring free cash flow and limiting M&A capacity. Higher rates also compress valuation multiples for healthcare services stocks trading at 10-12x EV/EBITDA. Conversely, rate cuts improve refinancing opportunities and reduce annual interest expense by $5-10M per 100bps decrease.

value - Stock trades at 0.7x P/S and 10.2x EV/EBITDA, below healthcare services peers at 1.2x P/S and 13x EV/EBITDA, attracting investors betting on operational turnaround, margin expansion from labor cost stabilization, and deleveraging. The 45% one-year return reflects recovery from COVID-era staffing disruptions, but negative net margin and high leverage deter growth investors. Recent 92% EPS growth suggests inflection point, appealing to deep-value funds focused on healthcare services consolidation.